About us
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
The GA4GH Council, consisting of the Executive Committee, Strategic Leadership Committee, and Product Steering Committee, guides our collaborative, globe-spanning alliance.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across a number of Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
Find out what’s happening with up to the minute meeting schedules for the GA4GH community.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Want to advance both your career and responsible genomic data sharing at the same time? See our open leadership opportunities.
Join our international team and help us advance genomic data use for the benefit of human health.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
22 Jun 2018
In an article recently published in the European Journal of Human Genetics, members of the Global Alliance for Genomics and Health (GA4GH) propose a new model for data access termed “registered access.” This tier between open access and controlled access aims to increase and improve access to genomic data for use in research.
In an article recently published in the European Journal of Human Genetics, members of the Global Alliance for Genomics and Health (GA4GH) propose a new model for data access termed “registered access.” This tier between open access and controlled access aims to increase and improve access to genomic data for use in research. It thereby furthers the impact those data can have on health and medicine and reinforces the human right to benefit from scientific advancement. The model is being piloted within the ELIXIR-Beacon network.
“Registered access builds on the strengths of the controlled access model, but it simplifies and streamlines the access process in a way we feel is suitable to the current research environment,” said lead author Stephanie Dyke, an ethics and policy researcher at McGill’s Montreal Neurological Institute and co-chair of the GA4GH Researcher Identities task team. “The landscape is changing — the number and scale of genomic datasets is growing and the number of researchers and other professionals, such as clinical care providers, who need to access those datasets is increasing. These potential data users need to seamlessly bring datasets from different sources together while maintaining important consent and privacy protections.”
Mikael Linden, the task co-leader of ELIXIR AAI, the ELIXIR service for researcher authentication and authorisation, added that the model allows for a greater focus on research: “Controlled access requires researchers to wait for their data access applications to be approved before commencing their investigations, which can cause a significant delay. If a researcher’s bona fide status has already been verified forregistered access, there is no lead-time, thereby reducing administration barriers and leaving more time for the actual research.”
Currently, data may exist in an open access tier, meaning they are publicly available on the World Wide Web, or in in a controlled access tier, meaning they are available to qualified researchers only for a specific project that has gone through a review process. In contrast, registered access would permit user access to a data environment after electronically verifying his/her identity and role (e.g., bona-fide researcher, clinical care professional) and obtaining an attestation of his/her agreement to a standard set of data usage responsibilities.
“All researchers should very easily be able to register, but they will need to agree to a standard set of good data use practices — the attestation.” said Dyke.
The work builds on previous research by a subset of the authors into the three-step approach: authorization, attestation, and authentication. Ideally, users make an attestation and register only once but their credentials are authenticated before each of their requests to access a data set are authorized.
“This model supports role-based access control, which is well established in other fields, including government and industry and can be implemented using existing technology standards widely used around the globe,” said Dixie Baker, a Senior Partner with Martin, Blanck & Associates, co-chair of the GA4GH Data Security Work Stream, and an author on the paper.
Work to standardize the technical details of the automation process and how registered access claims are represented is currently underway within GA4GH. The authors propose a user’s status is verified either by their home institution, or through proof of a professional license (for clinical care providers), or by another registered researcher. This approach is now being piloted within the ELIXIR-Beacon network, a GA4GH Driver Project.
“The model allows us to make ELIXIR data that is not consented for open access discoverable to the broader research community,” said Ilkka Lappalainen, Deputy Head of ELIXIR Finland and an author on the paper.
Registered access represents one of several aspects being explored by the GA4GH Work Streams to enable secure, privacy-protective data sharing to advance human health and medicine. For example, the GA4GH Researcher Identities Task Team is also developing a standard “library card” for genomic data which could allow researchers to use their registered access status across many resources.
“The GA4GH DURI Work Stream and the Data Security Work Stream are actively evolving the Library Card standards and GA4GH security protocols to support standardizing implementations that use the registered access tier,” said Moran Cabil, Senior Software Product Manager at the Broad Institute of MIT and Harvard, co-chair of the GA4GH Data Use task team, and an author on the paper.
Additional GA4GH Driver Projects are evaluating how registered access can be adopted within their data environments. Adoption across multiple projects will allow the broader community to evolve this important concept to accommodate the needs of different data custodians.
“Registered access is an important step for enabling and streamlining collaborative, international research across a federation of data repositories,” said Bartha Knoppers, Director of the Centre of Genomics and Policy at McGill University, co-chair of the GA4GH Regulatory and Ethics Work Stream, and an author on the paper.
NOTE: Research published by members of the GA4GH community does not necessarily reflect a approval as a GA4GH standard, a formal process which consists of five stages (proposed, submitted for approval, under review, approved, retired) and includes peer, security, and ethics reviews. Once approved, GA4GH specifications will be posted publicly with adequate documentation.